TG Therapeutics: A Look At New Briumvi Data And Ocrevus Zunovo Approval

(11min)

Summary

  • Shares of TG Therapeutics made new 52-week highs this week, helped in part by new Briumvi data presentations at ECTRIMS and despite Roche receiving FDA approval for Ocrevus Zunovo.
  • Ocrevus Zunovo's convenience profile does not look threatening and Roche believes it represents an incremental growth opportunity, primarily in treatment centers where IV infusions are not possible.
  • Convenience should also be the third consideration for patients, after efficacy and safety, and Briumvi's position on both still looks strong.
  • The new Briumvi data at ECTRIMS reinforce that switching from other multiple sclerosis therapies is seamless, and that the IV infusion of Briumvi can be completed in 30 minutes.
  • The focus now turns back to quarterly earnings updates from TG and its two key competitors.
  • Looking for more investing ideas like this one? Get them exclusively at Growth Stock Forum. Learn More »

Healthcare finance account report tablet pc stethoscope

mkurtbas/iStock via Getty Images

Shares of TG Therapeutics (NASDAQ:TGTX) made new 52-week highs this week, driven (at least in part) by additional data of Briumvi that I believe put the company in an even better position to take market share

I publish my best ideas and top coverage on the Growth Stock Forum. If you're interested in finding great growth stocks, with a focus on biotech, consider signing up. We focus on attractive risk/reward situations and track each of our portfolio and watchlist stocks closely. To receive e-mail notifications for my public articles and blogs, please click the follow button. And to go deeper, sign up for a free trial to Growth Stock Forum.

This article was written by

9.21K Followers

ONeil Trader is a former stockbroker turned full-time independent investor. He focuses on finding growth and biotech stocks with significant growth potential and calculates ideas in large part based on best risk-adjusted returns.

He leads the investing group Growth Stock Forum which features: a model portfolio of 15-20 names updated regularly, a top picks list of up to 10 stocks that are expected to perform well in the current calendar year, trading ideas that target both short-term and medium-term moves, and chat with community dialogue and for questions. Learn More.

Analyst’s Disclosure:I/we have a beneficial long position in the shares of TGTX either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

This article reflects the author's opinion and should not be regarded as a buy or sell recommendation or investment advice in any way.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Recommended For You

About TGTX Stock

SymbolLast Price% Chg
Market Cap
PE
Yield
Rev Growth (YoY)
Short Interest
Prev. Close
Compare to Peers

More on TGTX

Related Stocks

SymbolLast Price% Chg
TGTX
--